Codexis Expands Management Team — Announces Appointment of Kevin Taylor as Vice President of Business Development
Redwood City, CA - May 6, 2003Codexis, Inc. announced today the appointment of Kevin Taylor as Vice President of Business Development. In this role, Mr. Taylor will assume direct responsibility for Codexis’ global sales and marketing organization and execution of the company’s business development activities.
Mr. Taylor joins Codexis from Élan Corporation plc where he held the position of Director of Business Development since May 2001. In this capacity, Mr. Taylor was responsible for a broad range of commercial activities, including technology and product licensing deals, acquisition screening, and joint venture development. Prior to joining Élan, Mr. Taylor was the Business Unit General Manager, North America, for Zeneca’s Life Science Molecules Business Unit. In this role, Mr. Taylor was responsible for directing and managing new business development activities for small molecule and biotechnology opportunities in North America. His focus was on formulating and executing the company’s business strategy which involved providing process development and manufacturing services to the health care industry for a broad range of pharmaceutical products.
From 1993 to 1997, Mr. Taylor served as Sales and Marketing Manager for Cambrex Corporation, directing international sales, marketing and business development activities relating to the development and manufacture of pharmaceutical bulk actives as well as generic, cosmetic and personal care products. Mr. Taylor received his Bachelors of Science in Polymer Science and Chemistry from Pennsylvania State University and his Masters of Science in Management from the Wharton School of Business at the University of Pennsylvania.
“We are pleased to have someone of Kevin’s experience and track record join our senior management team,” said Alan Shaw, Ph.D., President and CEO of Codexis. “He has consistently demonstrated the ability to successfully establish customer relationships and grow revenues in Codexis’ key target markets, while providing key strategic and management support to senior management. Kevin’s addition underscores the progress Codexis has made to date in validating its technology and commercialization strategy. I look forward to Kevin’s critical contributions in helping the organization achieve its growth objectives.”
About Codexis
Codexis, Inc., a majority owned subsidiary of Maxygen, Inc., is a provider of biocatalysis and fermentation processes and products to the life science and fine chemical industries. Codexis’ proprietary MolecularBreeding™ directed molecular evolution technologies allow for the rapid discovery and development of improved or novel processes for the efficient and cost-effective synthesis of valuable chemicals utilizing breakthrough biocatalysts and production strains. Codexis offers its customers R&D services, proprietary biocatalysts and fermentation strains, processes, synthetic and natural products. Codexis has entered into nine strategic alliances in the chemicals field, and has over 19 potential products and processes in its R&D pipeline, with two product candidates in development. In addition, Codexis has five processes now operating at commercial scale, each generating royalty payments. The company is a majority owned subsidiary of Maxygen that commenced operations as an independent company in October of 2002. MolecularBreeding is a trademark of Maxygen, Inc.
Contact:
Codexis, Inc.
Tassos Gianakakos
Sr. Vice President, Business Development
T. +1-650-298-5423
F. +1-650-298-5449
tassos.gianakakos@codexis.com